CGEM – cullinan oncology, inc. (US:NASDAQ)
Stock Stats
News
Cullinan Therapeutics (NASDAQ:CGEM) had its price target raised by analysts at Wedbush from $25.00 to $34.00. They now have an "outperform" rating on the stock.
Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting
Cullinan Therapeutics (NASDAQ:CGEM) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
Cullinan Therapeutics (NASDAQ:CGEM) had its "buy" rating reaffirmed by analysts at BTIG Research.
Form 4 Cullinan Therapeutics, For: Dec 19 Filed by: Michaelson Jennifer
Form 4 Cullinan Therapeutics, For: Dec 18 Filed by: SUMER JACQUELYN L
Form 4 Cullinan Therapeutics, For: Dec 18 Filed by: Michaelson Jennifer
Form 4 Cullinan Therapeutics, For: Dec 18 Filed by: Jones Jeffrey Alan
Form 144 Cullinan Therapeutics, Filed by: Michaelson Jennifer
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.